Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

Impax Laboratories logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Key Stats

Today's Range
$17.40
$18.95
50-Day Range
$18.30
$18.30
52-Week Range
$13.05
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IPXL Stock News Headlines

Impax Global Environmental Markets Fd;Inv
Impax Large Cap Fund Individual Investor
First JFK… next Elon?
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
Impax International Sust Econ Instl
Impax US Sustainable Economy A
Impax Global Opportunities Institutional
Impax Sustainable Allocation Inv
Impax Sustainable Allocation Instl
See More Headlines

IPXL Stock Analysis - Frequently Asked Questions

Impax Laboratories, Inc. (NASDAQ:IPXL) issued its quarterly earnings data on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The firm's revenue for the quarter was down 9.4% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NovoCure (NVCR), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC) and Summit Midstream Partners (SMLP).

Company Calendar

Last Earnings
11/09/2017
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:IPXL) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners